AstraZeneca Pharma shares jump 12% to 52-week high on CDSCO permission

AstraZeneca Pharma India

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

AstraZeneca Pharma India share price rose 12.5 percent intraday on September 24 to hits 52-week high of 7,595 after the company received permission to import for sale & distribution of Durvalumab solution for Infusion.

At 12:21pm, AstraZeneca Pharma was quoting at Rs 7,537.15, up Rs 790.70, or 11.72 percent, on the BSE.

".... has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India," company said in exchange filing.

Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours 4 cm and/or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.

The receipt of this permission paves way for the launch of Durvalumab solution for infusion (Imfinzi) in India for the specified additional indication, subject to the receipt
of related statutory approvals, if any.

Catch all the market action on our live blog

Last week, company informed about launch of Palivizumab (Synagis) and Tremelimumab (Imjudo) in October 2024 in India.

Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC) and

Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease.

The share price gained 64 percent in the last one-year.